Based on the so far published data we selected seven candidate genes (TP53, CDKN2A, ataxia teleangiectasia mutated (ATM), B-cell lymphoma 2 (BCL2), oncogene MYC, retinoblastoma protein 1 (RB1) and cyclin-dependent kinase 4 (CDK4)), and analyzed their aberrations using fluorescent in-situ hybridization FISH in 126 consecutive patients with newly diagnosed MCL with bone marrow (BM) involvement ≥5%. This evidence concerns the gene RB1 and mantle cell lymphoma.